CytoDyn Inc. financial data

Symbol
CYDY on OTC
Industry
Pharmaceutical Preparations
Location
1111 Main Street, Suite 660, Vancouver, WA
State of incorporation
DE
Fiscal year end
May 31
Former names
REXRAY CORP (to 11/12/2003)
Latest financial report
10-Q - Q1 2025 - Apr 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 28.5 % +245%
Debt-to-equity -122 % -11.7%
Return On Equity 7.37 % -83.6%
Return On Assets -33.3 % +93%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.23B shares +24.1%
Common Stock, Shares, Outstanding 1.23B shares +24.5%
Entity Public Float 156M USD -47.2%
Common Stock, Value, Issued 1.23M USD +24.5%
Weighted Average Number of Shares Outstanding, Basic 1.23B shares +25.1%
Weighted Average Number of Shares Outstanding, Diluted 1.23B shares +25.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 7.24M USD +175%
General and Administrative Expense 8.44M USD -19.9%
Costs and Expenses -8.09M USD -153%
Operating Income (Loss) 8.09M USD -17.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.09M USD +86.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -7.09M USD +86.3%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.4M USD +1068%
Inventory, Net 0 USD
Assets, Current 21M USD +112%
Operating Lease, Right-of-Use Asset 163K USD -45.3%
Other Assets, Noncurrent 207K USD -42.5%
Assets 21.2M USD +106%
Accounts Payable, Current 15.1M USD -75.6%
Employee-related Liabilities, Current 224K USD +20.4%
Liabilities, Current 70.6M USD -45.5%
Operating Lease, Liability, Noncurrent 34K USD -80.7%
Other Liabilities, Noncurrent 43.6M USD
Liabilities 114M USD -11.9%
Retained Earnings (Accumulated Deficit) -882M USD -0.81%
Stockholders' Equity Attributable to Parent -93M USD +22.1%
Liabilities and Equity 21.2M USD +106%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 5.44M USD
Net Cash Provided by (Used in) Financing Activities 9.67M USD +141%
Common Stock, Shares Authorized 1.75B shares 0%
Common Stock, Shares, Issued 1.23B shares +24.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.4M USD +104%
Interest Paid, Excluding Capitalized Interest, Operating Activities 45K USD +87.5%
Deferred Tax Assets, Valuation Allowance 129M USD +0.04%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 129M USD +0.02%
Operating Lease, Liability 176K USD -44.7%
Depreciation 18K USD -28.6%
Lessee, Operating Lease, Liability, to be Paid 215K USD -46.3%
Operating Lease, Liability, Current 142K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Two 169K USD -8.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 169K USD -8.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 39K USD -52.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 169K USD -8.65%
Deferred Tax Assets, Operating Loss Carryforwards 101M USD +4.73%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 788M USD +4.41%
Deferred Tax Assets, Net of Valuation Allowance 55K USD -34.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%